61 related articles for article (PubMed ID: 21926398)
1. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Crea F; Fornaro L; Paolicchi E; Masi G; Frumento P; Loupakis F; Salvatore L; Cremolini C; Schirripa M; Graziano F; Ronzoni M; Ricci V; Farrar WL; Falcone A; Danesi R
Ann Oncol; 2012 May; 23(5):1207-1213. PubMed ID: 21926398
[TBL] [Abstract][Full Text] [Related]
2. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Loupakis F; Ruzzo A; Salvatore L; Cremolini C; Masi G; Frumento P; Schirripa M; Catalano V; Galluccio N; Canestrari E; Vincenzi B; Santini D; Bencardino K; Ricci V; Manzoni M; Danova M; Tonini G; Magnani M; Falcone A; Graziano F
BMC Cancer; 2011 Jun; 11():247. PubMed ID: 21669012
[TBL] [Abstract][Full Text] [Related]
3. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunakawa Y; Ning Y; Matsusaka S; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Soni S; Zhang W; Falcone A; Loupakis F; Lenz HJ
Ann Oncol; 2017 Nov; 28(11):2780-2785. PubMed ID: 29045529
[TBL] [Abstract][Full Text] [Related]
4. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.
Takawa M; Masuda K; Kunizaki M; Daigo Y; Takagi K; Iwai Y; Cho HS; Toyokawa G; Yamane Y; Maejima K; Field HI; Kobayashi T; Akasu T; Sugiyama M; Tsuchiya E; Atomi Y; Ponder BA; Nakamura Y; Hamamoto R
Cancer Sci; 2011 Jul; 102(7):1298-305. PubMed ID: 21539681
[TBL] [Abstract][Full Text] [Related]
5. EZH2 Expression and Survival for ER+/tamoxifen Treated Breast Cancer Patients with rs2302427 C>G: A Novel Prognostic and Risk Predictive Biomarker.
Gautam N; Kaur S; Kashyap S
Arch Med Res; 2023 Jul; 54(5):102852. PubMed ID: 37438214
[TBL] [Abstract][Full Text] [Related]
6. The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.
Vilorio-Marqués L; Martín V; Diez-Tascón C; González-Sevilla MF; Fernández-Villa T; Honrado E; Davila-Batista V; Molina AJ
Sci Rep; 2017 Oct; 7(1):13806. PubMed ID: 29061982
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.
Lim SH; Cho HJ; Kim KM; Lim HY; Kang WK; Lee J; Park YS; Kim HC; Kim ST
Oncol Res; 2023; 31(6):855-866. PubMed ID: 37744267
[TBL] [Abstract][Full Text] [Related]
8. Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer.
Wang D; Zhang X; Zhang Y; Wu Y; Guan X; Zhu W; Wang M; Qi C; Shen B
Onco Targets Ther; 2018; 11():8083-8088. PubMed ID: 30519050
[TBL] [Abstract][Full Text] [Related]
9. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.
Sanoff HK; Renfro LA; Poonnen P; Ambadwar P; Sargent DJ; Goldberg RM; McLeod H
PLoS One; 2014; 9(4):e94727. PubMed ID: 24727911
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide identification of chemosensitive single nucleotide polymorphism markers in colorectal cancers.
Kim JC; Kim SY; Cho DH; Roh SA; Choi EY; Jo YK; Jung SH; Na YS; Kim TW; Kim YS
Cancer Sci; 2010 Apr; 101(4):1007-13. PubMed ID: 20085586
[TBL] [Abstract][Full Text] [Related]
11. The potential of EZH2 expression to facilitate treatment choice in stage II colorectal adenocarcinoma.
Zhu X; He L; Zheng Z; Wang Y; Yang J; Zhang B; Wang C; Li Z
Histol Histopathol; 2024 Mar; ():18732. PubMed ID: 38567631
[TBL] [Abstract][Full Text] [Related]
12. EZH2 G553C significantly increases the risk of brain metastasis from lung cancer due to salt bridge instability.
Wang H; Wang L; Zhang S; Liu Q; Gao F
Cancer Cell Int; 2024 May; 24(1):175. PubMed ID: 38764053
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
[TBL] [Abstract][Full Text] [Related]
14. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.
de Bruin EC; McGranahan N; Mitter R; Salm M; Wedge DC; Yates L; Jamal-Hanjani M; Shafi S; Murugaesu N; Rowan AJ; Grönroos E; Muhammad MA; Horswell S; Gerlinger M; Varela I; Jones D; Marshall J; Voet T; Van Loo P; Rassl DM; Rintoul RC; Janes SM; Lee SM; Forster M; Ahmad T; Lawrence D; Falzon M; Capitanio A; Harkins TT; Lee CC; Tom W; Teefe E; Chen SC; Begum S; Rabinowitz A; Phillimore B; Spencer-Dene B; Stamp G; Szallasi Z; Matthews N; Stewart A; Campbell P; Swanton C
Science; 2014 Oct; 346(6206):251-6. PubMed ID: 25301630
[TBL] [Abstract][Full Text] [Related]
15. EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma.
Lu J; Zhao FP; Peng Z; Zhang MW; Lin SX; Liang BJ; Zhang B; Liu X; Wang L; Li G; Tian WD; Peng Y; He ML; Li XP
Oncotarget; 2014 Nov; 5(22):11319-32. PubMed ID: 25237831
[TBL] [Abstract][Full Text] [Related]
16. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
Gerlinger M; Horswell S; Larkin J; Rowan AJ; Salm MP; Varela I; Fisher R; McGranahan N; Matthews N; Santos CR; Martinez P; Phillimore B; Begum S; Rabinowitz A; Spencer-Dene B; Gulati S; Bates PA; Stamp G; Pickering L; Gore M; Nicol DL; Hazell S; Futreal PA; Stewart A; Swanton C
Nat Genet; 2014 Mar; 46(3):225-233. PubMed ID: 24487277
[TBL] [Abstract][Full Text] [Related]
17. Balancing of histone H3K4 methylation states by the Kdm5c/SMCX histone demethylase modulates promoter and enhancer function.
Outchkourov NS; Muiño JM; Kaufmann K; van Ijcken WF; Groot Koerkamp MJ; van Leenen D; de Graaf P; Holstege FC; Grosveld FG; Timmers HT
Cell Rep; 2013 Apr; 3(4):1071-9. PubMed ID: 23545502
[TBL] [Abstract][Full Text] [Related]
18. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Gerlinger M; Rowan AJ; Horswell S; Math M; Larkin J; Endesfelder D; Gronroos E; Martinez P; Matthews N; Stewart A; Tarpey P; Varela I; Phillimore B; Begum S; McDonald NQ; Butler A; Jones D; Raine K; Latimer C; Santos CR; Nohadani M; Eklund AC; Spencer-Dene B; Clark G; Pickering L; Stamp G; Gore M; Szallasi Z; Downward J; Futreal PA; Swanton C
N Engl J Med; 2012 Mar; 366(10):883-892. PubMed ID: 22397650
[TBL] [Abstract][Full Text] [Related]
19. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
Fornaro L; Faviana P; De Gregorio V; Vivaldi C; Paolicchi E; Masi G; Loupakis F; Sensi E; Lupi C; Fontanini G; Wang Y; Danesi R; Falcone A; Crea F
BMC Cancer; 2015 Nov; 15():874. PubMed ID: 26553291
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.
Maryan N; Statkiewicz M; Mikula M; Goryca K; Paziewska A; Strzałkowska A; Dabrowska M; Bujko M; Ostrowski J
Mol Med Rep; 2015 Jul; 12(1):728-36. PubMed ID: 25695204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
